Preparation method and application of composition containing pan jade extract

By combining Panlong jade with rapeseed polypeptide, a composition containing Panlong jade extract was prepared, which solved the problem of single and unstable functions of Panlong jade, significantly enhanced its effect on inhibiting melanin tumor cells, and Provides a safe, widely applicable natural therapeutic solution.

CN118903200AInactive Publication Date: 2024-11-08JILIN PANLONG JADE DEV CO LTD

Patent Information

Application Number
CN202411244375.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Panlong jade extract has a single function and is unstable, and it is difficult to be widely used in the fields of medicine and health care, and its binding to rapeseed polypeptides is rarely studied.

Method used

By crushing Panlong jade and sonicating it, combining it with rapeseed polypeptide, enzymatic decomposition and deionized water are used to adjust the pH value, and finally adding ethanol to freeze-dry the composition containing Panlong jade extract is prepared for anti-human melanoma proliferation.

Benefits of technology

Effectively extract and maintain the activity of trace elements in Panlong Jade, enhance its effect of inhibiting the growth of melanin tumor cells, and the composition has no toxic side effects, and is suitable for long-term consumption or auxiliary treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The invention relates to a preparation method and application of a composition containing a pan jade extract. The preparation method specifically comprises the following steps: S1, crushing and sieving pan jade to obtain pan jade powder, then adding a solvent, carrying out ultrasonic treatment, centrifuging, taking supernatant liquid, filtering, spin-drying filtrate, re-dissolving, and finally carrying out vacuum drying to obtain pan jade extract; s2, cleaning, drying and degreasing rapeseed meal to obtain rapeseed meal powder, then mixing the rapeseed meal powder with water, adding protease for enzymolysis, finally inactivating basic protein, performing centrifugal suction filtration to obtain a polypeptide solution, and performing freeze drying to obtain polypeptide powder; and S3, mixing the pan jade extract prepared in the step S1, the polypeptide powder prepared in the step S2 and deionized water, heating, adjusting the pH value, stirring to obtain a mixed solution, finally adding ethanol into the mixed solution, and carrying out centrifugal freeze drying to obtain the composition containing the pan jade extract. The composition containing the pan jade extract, prepared by the application, can effectively inhibit proliferation of human melanoma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of mineral extraction and preparation of its complexes, and specifically to a preparation method and application of a composition containing a Panlong jade extract. Background Art

[0002] In modern medicine and health science, natural extracts are rich in bioactive ingredients and have low adverse reaction characteristics, which have attracted much attention. Mineral medicines, with their long history and wide variety, reflect the profoundness of traditional Chinese medicine. According to statistics, there are more than 370 kinds of mineral medicines recorded in Chinese classics. Among them, "Shan Hai Jing", as an exploration of mineral medicines, first recorded information on more than 60 kinds of mineral medicines. In the latest 2020 edition of the "Chinese Pharmacopoeia", 23 kinds of mineral medicines are carefully selected and included, further confirming their important position in the modern medical system.

[0003] Jade has been loved by people for its warm touch and elegant color since ancient times. However, the medical and health value behind it cannot be ignored. As early as more than 2,000 years ago, jade was applied to the field of medical care. "Jade is the most beautiful stone, sweet and non-toxic", which is not only a summary of the characteristics of jade, but also an insight into its medicinal value. Panlong jade, with its black, black green, purple black and other colors, is rich in Li, As, B, Ba, Cr, Se, Cu and other mineral elements. In recent years, with the advancement of science and technology and the deepening of research, Panlong jade and its extracts have attracted much attention. The Chinese patent with announcement number CN 112022872A discloses a Panlong black jade extract and its preparation method and use. The application mentions that the Panlong black jade extract is obtained by extracting Panlong black jade with methanol, ethanol or water for anti-tumor. However, the Panlong black jade extract obtained in the application is difficult to exist stably, and its direct use is limited and its function is single. This prompts us to continuously explore new paths in order to optimize the performance of Panlong jade extract and expand its application range.

[0004] Rapeseed meal is the remaining material after oil extraction from rapeseed, sunflower seeds, etc. Rapeseed meal is not only traditionally used as an additive for animal feed, but also contains rich nutritional value and biological activity. Through modern biotechnology, rapeseed peptides extracted from rapeseed meal provide rich nutritional support for the body with their unique structure of small molecule short-chain peptides, and show a series of health benefits such as lowering blood pressure, anti-oxidation, anti-coagulation and anti-cancer. However, there are few reports on the combination of Panlongyu extract and rapeseed peptides.

[0005] In view of this, this application has made an innovative attempt based on existing research, combining Panlongyu extract with rapeseed peptide, aiming to create a new natural product composition that combines high efficiency, low side effects and wide applicability through the synergistic effect of the two, improve the overall efficacy and stability, and provide new ideas for the fields of medicine and health care. Summary of the invention

[0006] In view of the problems of single function and instability of Panlongyu extract in the background technology, and combining the advantages of rapeseed polypeptide, the present application proposes a preparation method and application of a composition containing Panlongyu extract.

[0007] The technical solution of this application:

[0008] On the one hand, the present application provides a method for preparing a composition containing a Panlongyu extract, comprising the following steps:

[0009] Step S1. crushing and sieving the Panlong jade to obtain Panlong jade powder, then adding a solvent for ultrasonic treatment, centrifuging to obtain the supernatant, filtering, and spinning the filtrate to dryness, then redissolving, and finally vacuum drying to obtain the Panlong jade extract;

[0010] Step S2. The rapeseed meal is washed, dried and defatted to obtain rapeseed meal powder, and then the rapeseed meal powder is mixed with water, and protease is added for enzymolysis, and finally the alkaline protein is inactivated, and a polypeptide solution is obtained by centrifugal filtration, and freeze-dried to obtain polypeptide powder;

[0011] Step S3. Mix the Panlongyu extract prepared in step S1, the polypeptide powder prepared in step S2 and deionized water, adjust the pH value after heating, and stir to obtain a mixed solution. Finally, add ethanol to the mixed solution, centrifuge and freeze-dry to obtain a composition containing the Panlongyu extract.

[0012] Preferably, in step S1, the Panlong jade powder is sieved through a 400-mesh sieve, the solvent is any one of methanol and ethanol, the ratio of the Panlong jade powder to the solvent is 1 g:(50-100 mL), the ultrasonic treatment time is 1-2 h, and the filtration is a 0.22 μm filter membrane.

[0013] Preferably, the degreasing agent selected for degreasing in step S2 is any one of acetone or ethyl acetate, the rapeseed meal is any one of rapeseed meal or sunflower seed meal, and the ratio of rapeseed to the degreasing agent is 1g:(20-30mL).

[0014] Preferably, the protease in step S2 is any one of subtilis protease, Novo protease or Carsberg protease; when subtilis protease is selected, the pH value is adjusted to 7-8; when Novo protease or Carsberg protease is selected, the pH value is adjusted to 6-10; the ratio of rapeseed meal to water is 1g:(20-30mL); the mass of the protease accounts for 1-4% of the rapeseed meal.

[0015] Preferably, the enzymatic hydrolysis temperature in step S2 is 40-50° C., the enzymatic hydrolysis method is ultrasonication for 15 min, stirring for 40 min, and ultrasonic stirring is repeated once; and the inactivation is carried out in a water bath for 10-15 min.

[0016] Preferably, the mass ratio of the Panlongyu extract, polypeptide powder and deionized water in step S3 is 1:2:(5-10), the pH value is 7-8, the heating temperature is 40-60°C, the stirring time is 30-60min, and the volume of ethanol added is 8-10 times that of the mixed solution.

[0017] On the other hand, the present application provides an application of a composition containing a Panlongyu extract for inhibiting the proliferation of human melanoma.

[0018] Beneficial effects of this application:

[0019] (1) The Panlongyu extract selected in the present application is rich in a variety of trace elements, such as selenium, zinc, iron, etc. These trace elements have important biological functions. Through the preparation method of the present application, these beneficial components in the Panlongyu can be effectively extracted and remain active in the composition. The trace elements in the Panlongyu extract can inhibit the growth and spread of tumor cells directly or through indirect pathways such as regulating the body's immune system.

[0020] (2) As a hydrolyzate of plant protein, rapeseed peptide not only retains the nutritional value of protein, but also has a high bioavailability. It is rich in active ingredients such as amino acids and peptides, which have a positive effect on enhancing the body's immunity and promoting cell repair. The unique structure and properties of rapeseed peptide can also promote the absorption of minerals and trace elements. At the same time, rapeseed peptide can form a protective layer in the gastrointestinal tract, reduce the inflammatory response of the gastrointestinal mucosa, and protect the gastrointestinal tract from the stimulation of harmful substances. Therefore, after the rapeseed peptide is combined with the Panlongyu extract, it can promote the absorption rate of trace elements in the Panlongyu and further enhance its effect of inhibiting the proliferation of melanoma tumors. The combination of Panlongyu extract and rapeseed peptide enhances its effect of inhibiting melanoma through synergistic effects.

[0021] (3) The composition of the present application is prepared from natural raw materials, without chemical additives, and has no toxic side effects on the human body. It is suitable for long-term consumption or as an auxiliary treatment method. DETAILED DESCRIPTION

[0022] In order to further explain the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation method, structure, characteristics and effects of the present invention are described in detail below in combination with the preferred embodiments.

[0023] Example 1

[0024] This embodiment provides a method for preparing a composition containing a Panlongyu extract, comprising the following steps:

[0025] Step S1. Mechanically crush the Panlong jade collected from Longgang Mountains in Panshi City, Jilin Province, and pass it through a 400-mesh sieve to obtain Panlong jade powder. Then, take 10 g of Panlong jade powder and add it to 350 mL of methanol, ultrasonically treat it for 1 hour, centrifuge it at 4000 rpm for 30 minutes, take the supernatant and filter it with a 0.22 μm filter membrane, and spin-dry the filtrate at 55°C, then dissolve it with 1 mL of methanol, and finally vacuum dry it at 80°C to obtain the Panlong jade extract.

[0026] Step S2. 10 g of rapeseed meal was washed twice, and then filtered to remove the filtrate, and dried at 50° C. for 3 h to obtain dried rapeseed meal, and then 8 g of dried rapeseed meal was mixed with 25 mL of acetone, stirred at room temperature for 1 h, and centrifuged to remove the acetone to obtain defatted rapeseed meal, and then 6 g of defatted rapeseed meal was added with 25 g of water and 0.12 g of Bacillus subtilis protease to adjust the pH to 8 for enzymolysis, the enzymolysis temperature was 45° C., ultrasonic for 15 min, and then stirred for 40 min, and ultrasonic stirring was repeated once; finally, the Bacillus subtilis protease was extinguished in a 70° C. water bath for 12 min, and the rapeseed polypeptide solution was obtained by centrifugation at 4000 rpm for 30 min, and the rapeseed polypeptide powder was obtained by freeze drying at -70° C. to remove moisture;

[0027] Step S3. Mix 0.5 g of the Panlongyu extract prepared in step S1, 1 g of the rapeseed polypeptide powder prepared in step S2 and 8 g of deionized water, then adjust the pH value to 7, raise the temperature to 50°C, and stir for 45 minutes to obtain a mixed solution. Finally, add 81 mL of ethanol to the mixed solution, centrifuge at 4000 rpm for 30 minutes, and freeze-dry at -70°C to obtain a composition containing the Panlongyu extract.

[0028] Example 2

[0029] This embodiment provides a method for preparing a composition containing a Panlongyu extract, comprising the following steps:

[0030] Step S1. Mechanically crush the Panlong jade collected from Longgang Mountains in Panshi City, Jilin Province, and pass it through a 400-mesh sieve to obtain Panlong jade powder. Then, take 10 g of Panlong jade powder and add it to 250 mL of ethanol, ultrasonically treat it for 1.5 hours, centrifuge it at 4000 rpm for 30 minutes, take the supernatant and filter it with a 0.22 μm filter membrane, and spin-dry the filtrate at 55°C, then dissolve it with 1 mL of ethanol, and finally vacuum dry it at 80°C to obtain the Panlong jade extract.

[0031] Step S2. Take 10g of sunflower seed meal, wash it twice, filter and remove the filtrate, dry it at 50℃ for 3h to obtain dried sunflower seed meal, then take 8g of dried sunflower seed meal and mix it with 20mL of ethyl acetate, stir it at room temperature for 1h, centrifuge to remove ethyl acetate, and obtain defatted sunflower seed meal, then add 20g of water and 0.06g of Novo protease to 6g of defatted sunflower seed meal, adjust the pH to 8 for enzymolysis, the enzymolysis temperature is 50℃, ultrasonicate for 15min, then stir for 40min, repeat ultrasonic stirring once; finally, extinguish the Bacillus subtilis protease in a water bath at 70℃ for 10min, centrifuge at 4000rpm for 30min to obtain a rapeseed polypeptide solution, and dry it at -70℃ to remove moisture to obtain rapeseed polypeptide powder;

[0032] Step S3. Mix 0.5 g of the Panlongyu extract prepared in step S1, 1 g of the sunflower polypeptide powder prepared in step S2 and 5 g of deionized water, then adjust the pH value to 8, raise the temperature to 60°C, and stir for 30 minutes to obtain a mixed solution. Finally, add 60 mL of ethanol to the mixed solution, centrifuge at 4000 rpm for 30 minutes, and freeze-dry at -70°C to obtain a composition containing the Panlongyu extract.

[0033] Example 3

[0034] This embodiment provides a method for preparing a composition containing a Panlongyu extract, comprising the following steps:

[0035] Step S1. The Panlong jade collected from Longgang Mountains in Panshi City, Jilin Province was mechanically crushed and passed through a 400-mesh sieve to obtain Panlong jade powder. Subsequently, 10 g of Panlong jade powder was added to 500 mL of methanol, ultrasonically treated for 2 h, centrifuged at 4000 rpm for 30 min, the supernatant was filtered with a 0.22 μm filter membrane, and the filtrate was spin-dried at 55° C., then re-dissolved with 1 mL of methanol, and finally vacuum-dried at 80° C. to obtain a Panlong jade extract.

[0036] Step S2. Take 10g of rapeseed meal and wash it twice, then filter and remove the filtrate, and dry it at 50℃ for 3h to obtain dried rapeseed meal, then take 8g of dried rapeseed meal and mix it with 30mL of acetone, stir it at room temperature for 1h, and centrifuge to remove acetone to obtain defatted rapeseed meal, then add 30g of water to 6g of defatted rapeseed meal, and adjust the pH to 7 with 0.24g of Carsberg protease for enzymolysis, the enzymolysis temperature is 40℃, ultrasonic for 15min, then stir for 60min, and repeat ultrasonic stirring once; finally, extinguish the Bacillus subtilis protease in a water bath at 70℃ for 15min, centrifuge at 4000rpm for 30min to obtain a rapeseed polypeptide solution, and freeze-dry at -70℃ to remove moisture to obtain rapeseed polypeptide powder;

[0037] Step S3. Mix 0.5 g of the Panlongyu extract prepared in step S1, 1 g of the rapeseed polypeptide powder prepared in step S2 and 10 g of deionized water, then adjust the pH value to 7, raise the temperature to 40°C, and stir for 60 minutes to obtain a mixed solution. Finally, add 88 mL of ethanol to the mixed solution, centrifuge at 4000 rpm for 30 minutes, and freeze-dry at -70°C to obtain a composition containing the Panlongyu extract.

[0038] Animal test examples

[0039] The names, models and numbers of the main instruments involved in this test example are shown in Table 1.

[0040] Table 1

[0041] Device Name Manufacturer model Instrument No. Incubator Hong Kong Likang HF751 YQ010012 Clean bench Kazakhstan East Union DJ-CJ-2NDI YQ070006 Centrifuge Hunan Kecheng H4-20KR YQ050002 Ultra-low temperature refrigerator Haier DW-86L388J YQ040031 Pipette Big Dragon 0.1-1mL YQ100009

[0042] 1. Information on experimental animals used in this application:

[0043] Species: B-NDG mice;

[0044] Grade: SPF grade;

[0045] Gender: female;

[0046] Age: 4 to 5 weeks old when purchased, 6 to 8 weeks old when grouped;

[0047] Source: Beijing Biocytogen Biotech Co., Ltd.

[0048] 2. Reasons for choosing B-NDG mice:

[0049] B-NDG mice (NOD-Prkdc scid IL tm1 / Bcgen) is a highly immunodeficient mouse independently developed by Biocytogen. It is an IL2rg gene knockout mouse with a NOD-scid genetic background. It lacks mature T, B and NK cells and is currently recognized as a tool mouse with a high degree of immunodeficiency and suitable for human cell or tissue transplantation.

[0050] B-NDG mice have the following advantages:

[0051] (1) It is a recognized severe immunodeficient mouse;

[0052] (2) Compared with NOD-scid mice, they have a longer lifespan, up to 1.5 years on average;

[0053] (3) There is almost no rejection reaction to human cells and tissues;

[0054] (4) A small number of cells can form a tumor, which depends on the cell line or cell type;

[0055] (5) No B lymphocyte leakage.

[0056] Selection of animal strains and numbers: Follow the 3R principle, which not only meets the scientific needs of research objectives and model establishment, but also complies with current scientific standards and guidelines.

[0057] 3. Tumor cells:

[0058] Name or code: Human malignant melanoma cell A375;

[0059] Source: China Center for Type Culture Collection (CCTCC);

[0060] Morphological features: epithelial cell-like;

[0061] Growth characteristics: adherent growth;

[0062] Culture conditions: 89% RMPI1640 + 10% FBS + 1% penicillin-streptomycin;

[0063] Cryopreservation conditions: 60% culture medium + 30% fetal bovine serum + 10% DMSO, cryopreserved in liquid nitrogen;

[0064] Protective measures: General protection, wear work clothes, masks and gloves.

[0065] 4. Experimental process

[0066] Malignant melanoma is a highly malignant tumor with early metastasis and high mortality rate. It is mainly caused by the canceration of nerve sheath melanocytes. The incidence of malignant melanoma is increasing year by year, and the clinical prognosis is poor. The 2-year survival rate of patients in the advanced stage is about 15%. In this experimental example, a subcutaneous transplant tumor model of human malignant melanoma cells A375 was established in B-NDG mice to observe the in vivo anti-tumor efficacy of Panlongyu extract, a composition containing Panlongyu extract, and cisplatin on this model. A control group A and experimental groups B to F were set up, and the injection drugs of each group are shown in Table 2. A suspension of human malignant melanoma A375 cells in the logarithmic growth phase was taken at 5×10 6 The B-NDG mouse transplant tumor model was established by inoculating cells / mouse under the armpit, and the average tumor volume was screened to be 100-150mm 3 64 female B-NDG mice were randomly divided into 8 groups, 1 to 8 groups were control group AA (normal saline), experimental group B (cisplatin, 5 mg / kg), experimental group C (1 g / kg), experimental group D (1.5 g / kg), experimental group E (1.5 g / kg), experimental group F (1.5 g / kg), 8 mice in each group, and the number of each group is shown in Table 3. The administration began on the day of grouping (recorded as D1), cisplatin injection was intraperitoneally injected once a week, normal saline, Panlongyu extract and the composition containing Panlongyu extract were gavaged once a day, and the experimental period was 25 days. During the experiment, the general state of the mice was observed every day, the weight of the mice was measured on the 1st, 4th, 8th, 11th, 15th, 18th, 22nd, and 25th days, and the tumor mass was measured when euthanized on the 25th day. The results are shown in Tables 4 to 8, and the therapeutic effects of the composition containing Panlongyu extract and cisplatin on the growth of tumors in this model were evaluated.

[0067] Basis for test sample dosage design: The results of the previous preliminary test showed that the extract of Panlongyu powder had an inhibition rate of 33% on the tumor weight of the A375 mouse subcutaneous transplanted tumor model of malignant melanoma cells at a dose of 0.5g / kg, and had a tendency to delay tumor proliferation. This experiment intends to increase the dosage of the test substance, and the dosage is set at 1g / kg and 2g / kg to further examine the anti-tumor efficacy of the test substance.

[0068] Reference substance dosage design basis: Cisplatin injection was used as the chemotherapy drug control group, and the mouse dosage was calculated by body surface area normalization method with reference to the clinical adult dosage. According to the instructions for cisplatin injection, the general dosage of cisplatin is 20 mg / m2 per time based on body surface area. 2, once a day for five consecutive days. The adult weight is calculated as 70kg, and the adult dosage is about 0.47mg / kg. After the mouse weight is converted to 20g, the mouse dosage is 5.48mg / kg. The test center has proved through many tests that the anti-tumor effect is obvious when the cisplatin treatment dose is 5.0mg / kg. Therefore, the dose of cisplatin in this experiment is set to 5.0mg / kg.

[0069] 5. Detection indicators

[0070] (1) General clinical observation

[0071] Observed animals: All living animals;

[0072] Observation time and frequency: Starting from the inoculation, observe the general condition of the animals once in the morning and once in the afternoon every day.

[0073] Observation content: including but not limited to the animal's physical appearance, general behavior, mental state, glandular secretions, respiratory status, fecal characteristics, dying and death conditions, etc.

[0074] (2) Mouse weight

[0075] Animals to be measured: All living animals, including any dead animals found at any time, must also be weighed and recorded;

[0076] Measurement time and frequency: Receiving quarantine, twice a week after vaccination (including the day of grouping); twice a week after administration; Measurement method: refer to the requirements of SOP TEC-01-10 "Measurement of body weight of experimental animals".

[0077] (3) Tumor volume

[0078] Animals to be measured: All living animals, including any dead animals found at any time, must also be weighed and recorded;

[0079] Measurement time and frequency: During the modeling period and after the start of drug administration, measurements were taken twice a week;

[0080] Measurement method: Use a vernier caliper to measure and record the long and short diameters of the tumor.

[0081] (4) Tumor weight

[0082] Test animals: All surviving animals in each group;

[0083] Measurement time and frequency: weigh once after euthanasia at the end of the modeling experiment;

[0084] Determination method: According to the requirements of SOP ANI-05-02 "Euthanasia of Laboratory Animals" and PAT-01-27 "Dissection of Rodents", the tumor was removed after the mouse was euthanized and weighed on an electronic balance.

[0085] 6. Evaluation Criteria

[0086] (1) Tumor volume

[0087] The tumor volume was calculated based on the long and short diameters of the tumor. The calculation formula is:

[0088] Tumor volume TV = 1 / 2 × a × b 2

[0089] a: the long diameter of the tumor, b: the short diameter of the tumor.

[0090] (2) Tumor proliferation rate T / C (%)

[0091] Tumor proliferation rate, T / C (%), is the percentage of the relative tumor volume of the treatment group and the control group at a certain time point. The calculation formula is:

[0092] RTV=V t / V0,V t : The tumor volume obtained each time the tumor was measured; V0: initial tumor volume (before administration)

[0093] T / C% = T RTV / C RTV ×100%(T RTV : Average RTV of the treatment group; C RTV : Average RTV of the control group)

[0094] If T / C%>40%, it is ineffective; if T / C%≤40% and P<0.05, it is effective.

[0095] (3) Tumor weight

[0096] The tumor weight inhibition rate of each group was calculated according to the tumor weight. The calculation formula is:

[0097] Tumor weight inhibition rate IR (%) = (1-TW t / TW c )×100%

[0098] TW t : Tumor weight of treatment group; TW c : Tumor weight of negative control group.

[0099] Table 2

[0100] Group Add drug type Control group A Normal saline Experimental Group B Cisplatin Experimental Group C Composition containing Panlongyu extract prepared in Example 1 Experimental Group D Panlongyu Extract Experimental Group E Cisplatin combined with Panlongyu extract Experimental Group F Cisplatin combined with the composition containing the Panlongyu extract prepared in Example 1

[0101] Table 3

[0102]

[0103] Test results:

[0104] Table 4 Body weight of animals in each group

[0105]

[0106]

[0107] Note: 1.6F001 died on D15; 6F007 died on D18; Group 3 and Group 4 were euthanized on D23; Group 1, Group 2, Group 5 and Group 6 were euthanized on D25;

[0108] 2. “-” indicates the animal is dead;

[0109] 3. " * "Indicates that there is a significant difference compared with the control group A, P ≤ 0.05;" *** ” indicates that there is a significant difference compared with the control group A, P ≤ 0.001.

[0110] Table 5(1 / 2) Average tumor volume of animals in each group

[0111]

[0112] Note: 1.6F001 died on D15; 6F007 died on D18; Group 3 and Group 4 were euthanized on D23; Group 1, Group 2, Group 5 and Group 6 were euthanized on D25;

[0113] 2.“-” indicates the animal is dead.

[0114] Table 5 (2 / 2) Average tumor volume of animals in each group

[0115]

[0116] Note: 1.6F001 died on D15; 6F007 died on D18; Group 3 and Group 4 were euthanized on D23; Group 1, Group 2, Group 5 and Group 6 were euthanized on D25;

[0117] 2.“-” indicates the animal is dead.

[0118] Table 6 (1 / 2) Average relative tumor volume of animals in each group (X ± SD)

[0119]

[0120] Note: 1.6F001 died on D15; 6F007 died on D18; Group 3 and Group 4 were euthanized on D23; Group 1, Group 2, Group 5 and Group 6 were euthanized on D25;

[0121] 2. “*” indicates that there is a significant difference compared with the control group A, P≤0.05; “***” indicates that there is a significant difference compared with the control group A, P≤0.001.

[0122] Table 6(2 / 2) Relative average tumor volume of animals in each group

[0123]

[0124] Note: 1.6F001 died on D15; 6F007 died on D18; Group 3 and Group 4 were euthanized on D23; Group 1, Group 2, Group 5 and Group 6 were euthanized on D25;

[0125] 2. “-” indicates the animal is dead;

[0126] 3. " * "Indicates that there is a significant difference compared with the control group A, P ≤ 0.05;" ** "Indicates that there is a significant difference compared with the control group A, P ≤ 0.01;" *** ” indicates that there is a significant difference compared with the control group A, P ≤ 0.001.

[0127] Table 7 Relative tumor proliferation rate T / C (%) of each group of animals

[0128]

[0129]

[0130] Note: 1.6F001 died on D15; 6F007 died on D18; Group 3 and Group 4 were euthanized on D23; Group 1, Group 2, Group 5 and Group 6 were euthanized on D25;

[0131] 2.“-” indicates the animal is dead.

[0132] Table 8 Tumor weight and tumor weight inhibition rate IR (%)

[0133] Group Tumor weight (g) IR(%) Control group A 1.6785±0.6478 Experimental Group B <![CDATA[0.7145±0.4653 ** ]]> 57.43 Experimental Group C 1.0511±1.1336 - Experimental Group D 1.3489±0.5616 - Experimental Group E <![CDATA[0.3713±0.3786 *** ]]> 77.88 Experimental Group F <![CDATA[0.1915±0.1949 *** ]]> 88.59

[0134] Note: 1.6F001 died on D15; 6F007 died on D18; Group 3 and Group 4 were euthanized on D23; Group 1, Group 2, Group 5 and Group 6 were euthanized on D25;

[0135] 2. “-” indicates the animal is dead;

[0136] 3. " ** "Indicates that there is a significant difference compared with the control group A, P ≤ 0.01;" *** ” indicates that there is a significant difference compared with the control group A, P ≤ 0.001.

[0137] During the whole experiment, the control group A, experimental group C and experimental group D were in good condition, without abnormality and animal death. The average weight of animals in each group continued to increase, and there was no difference between the groups (P>0.05). Two animals (6F001 and 6F007) in experimental group E died on D15 and D18 respectively. Animals in experimental groups C and D were euthanized on D23, and the rest of the animals were euthanized at the end of the experiment, D25. On D4, D11, and D15, compared with control group A, the average weight of mice in experimental group B was lower than that in experimental group F, and there was a significant difference between them and experimental group F (P<0.05); since D4, the average weight of experimental groups E and experimental groups F was significantly lower than that of experimental group F, and there was a statistical difference between them and experimental group F (P<0.05). By the end of the experiment, the average body weights of animals in groups 1 to 6 were 23.14±2.40g, 22.61±1.18g, 21.73±1.83g, 24.38±1.93g, 19.83±2.88g, and 18.03±3.54g, respectively.

[0138] D25, the average tumor volume of control group A was 2691.88±594.05mm 3 The average tumor volumes of experimental groups B, E, and F were 1269.37±723.73mm 3 、825.55±393.10mm 3 、526.03±278.51mm 3 Compared with control group A, there were statistical differences (P = 0.010, <0.001, 0.001, respectively); the tumor inhibition rates T / C (%) of experimental group B, experimental group E and experimental group F were 49.95%, 32.56%, and 18.88%, respectively. Compared with experimental group B, experimental group E had no statistically significant difference (P = 0.195); but compared with experimental group B and experimental group F, there were statistically significant differences (P = 0.013).

[0139] At D25, the average tumor weight of control group A was 1.6785±0.6478g, and the average tumor weights of experimental groups B, E, and F were 0.7145±0.46532g, 0.3713±0.3786g, and 0.1915±0.1949g, respectively, which were significantly different from those of control group A (P=0.005, 0.001, and 0.001, respectively). The average tumor inhibition rates were 57.43%, 77.88%, and 88.59%, respectively. Compared with experimental group B, experimental group E had no statistically significant difference (P=0.105); but compared with experimental group B, experimental group F had a statistically significant difference (P=0.005).

[0140] in conclusion:

[0141] Under the experimental conditions, a subcutaneous transplant tumor model of human melanoma cell A375 in B-NDG mice was successfully established.

[0142] Cisplatin injection at a dose of 5 mg / kg had a significant inhibitory effect on tumor growth in terms of tumor volume and tumor weight, and no mice died.

[0143] There was no statistically significant difference in tumor weight or tumor volume between experimental group C and experimental group D and control group A, and they did not show a good inhibitory effect on mouse tumor growth. However, under the experimental conditions, it can be seen that the combination of Panlongyu extract and polypeptide has a good inhibitory effect in experimental group C and experimental group D.

[0144] Experimental groups E and F both showed statistically significant inhibitory effects on tumor growth in terms of tumor volume and tumor weight, and compared with experimental group B, experimental group D had statistically significant differences.

[0145] The weight of mice in experimental group E decreased significantly, and 2 / 8 mice in experimental group F died, indicating that B-NDG mice had a certain inhibitory effect on mice in the B-NDG mouse subcutaneous transplant tumor model of human melanoma cell A375 when used in experimental group E or experimental group F.

[0146] It is further proved that the unique structure and properties of the rapeseed polypeptide of the present application can promote the absorption of minerals and trace elements. At the same time, the rapeseed polypeptide can form a protective layer in the gastrointestinal tract, reduce the inflammatory response of the gastrointestinal mucosa, and protect the gastrointestinal tract from the stimulation of harmful substances. Therefore, after the rapeseed polypeptide is combined with the Panlongyu extract, it can promote the absorption rate of trace elements in the Panlongyu, and further enhance its effect of inhibiting the proliferation of melanoma tumors.

[0147] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A method for preparing a composition containing a Panlongyu extract, characterized in that: The steps include: Step S1. crushing and sieving the Panlong jade to obtain Panlong jade powder, then adding a solvent for ultrasonic treatment, centrifuging to obtain the supernatant, filtering, and spinning the filtrate to dryness, then redissolving, and finally vacuum drying to obtain the Panlong jade extract; Step S2. The rapeseed meal is washed, dried and defatted to obtain rapeseed meal powder, and then the rapeseed meal powder is mixed with water, and protease is added for enzymolysis, and finally the alkaline protein is inactivated, and a polypeptide solution is obtained by centrifugal filtration, and freeze-dried to obtain polypeptide powder; Step S3. Mix the Panlongyu extract prepared in step S1, the polypeptide powder prepared in step S2 and deionized water, adjust the pH value after heating, and stir to obtain a mixed solution. Finally, add ethanol to the mixed solution, centrifuge and freeze-dry to obtain a composition containing the Panlongyu extract.

2. The method for preparing a composition containing a Panlongyu extract according to claim 1, characterized in that: In the step S1, the Panlong jade powder is passed through a 400-mesh sieve, the solvent is any one of methanol and ethanol, the ratio of the Panlong jade powder to the solvent is 1 g:(50-100 mL), the ultrasonic treatment time is 1-2 h, and the filtration is a 0.22 μm filter membrane.

3. The method for preparing a composition containing a Panlongyu extract according to claim 1, characterized in that: The degreasing agent selected for degreasing in step S2 is any one of acetone or ethyl acetate, the rapeseed meal is any one of rapeseed meal or sunflower seed meal, and the ratio of rapeseed to the degreasing agent is 1g:(20-30mL).

4. The method for preparing a composition containing a Panlongyu extract according to claim 1, characterized in that: The protease in step S2 is any one of subtilis protease, Novo protease or Carsberg protease; when subtilis protease is selected, the pH value is adjusted to 7-8; when Novo protease or Carsberg protease is selected, the pH value is adjusted to 6-10; the ratio of rapeseed meal to water is 1g:(20-30mL); the mass of the protease accounts for 1-4% of the rapeseed meal.

5. The method for preparing a composition containing a Panlongyu extract according to claim 1, characterized in that: The enzymatic hydrolysis temperature in step S2 is 40-50° C., the enzymatic hydrolysis method is ultrasonic for 15 minutes, stirring for 40 minutes, and repeating ultrasonic stirring once; the inactivation is carried out in a water bath for 10-15 minutes.

6. The method for preparing a composition containing a Panlongyu extract according to claim 1, characterized in that: The mass ratio of the Panlongyu extract, polypeptide powder and deionized water in step S3 is 1:2:(5-10), the pH value is 7-8, the heating temperature is 40-60°C, the stirring time is 30-60 minutes, and the volume of ethanol added is 8-10 times that of the mixed solution.

7. An application of a composition containing a Panlongyu extract, based on the preparation method of a composition containing a Panlongyu extract according to any one of claims 1 to 6, characterized in that: Used to inhibit the proliferation of human melanoma.

Citation Information

Patent Citations

  • Flour from the cake of the Favela seed for antioxidant and nutraceutical applications.

    BR102018016876A2

  • Panlong black jade extract and preparation method and application thereof

    CN112022872A

  • Chinese cabbage seed extract and application thereof

    CN113456685A

Cited By

  • Method for preparing nano-composite containing pan jade extract and application of nano-composite

    CN119386040A